Open-Label Study of 18F-mFBG for Imaging Neuroblastoma
Status:
Recruiting
Trial end date:
2022-12-01
Target enrollment:
Participant gender:
Summary
This is a Phase 3 study evaluating the positron-emitting radiopharmaceutical 18F-mFBG as an
imaging agent for confirming or excluding the presence of neuroblastoma
Phase:
Phase 3
Details
Lead Sponsor:
Illumina Radiopharmaceuticals, LLC
Collaborators:
Memorial Sloan Kettering Cancer Center New Approaches to Neuroblastoma Therapy Consortium